company background image
AUPH logo

Aurinia Pharmaceuticals NasdaqGM:AUPH Stock Report

Last Price

US$7.36

Market Cap

US$1.1b

7D

5.3%

1Y

3.2%

Updated

30 Oct, 2024

Data

Company Financials +

Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH Stock Report

Market Cap: US$1.1b

AUPH Stock Overview

A commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.

AUPH fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Aurinia Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aurinia Pharmaceuticals
Historical stock prices
Current Share PriceUS$7.36
52 Week HighUS$10.05
52 Week LowUS$4.71
Beta1.44
11 Month Change0.41%
3 Month Change31.19%
1 Year Change3.23%
33 Year Change-75.78%
5 Year Change39.13%
Change since IPO259.02%

Recent News & Updates

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Recent updates

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Aurinia Pharmaceuticals Appears Undervalued

Jul 05

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)

May 02

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024

Apr 18

Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed

Mar 05

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon

Feb 15

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential

Jan 28

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Jan 05
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Dec 18
Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Sep 14
Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Jun 11
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

May 09
Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

May 01
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus

Sep 19

Aurinia Pharmaceuticals: The Right Play Now

Aug 24

Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model

Aug 15

Shareholder Returns

AUPHUS BiotechsUS Market
7D5.3%-0.2%-0.09%
1Y3.2%27.0%38.6%

Return vs Industry: AUPH underperformed the US Biotechs industry which returned 27% over the past year.

Return vs Market: AUPH underperformed the US Market which returned 38.6% over the past year.

Price Volatility

Is AUPH's price volatile compared to industry and market?
AUPH volatility
AUPH Average Weekly Movement6.5%
Biotechs Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: AUPH has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: AUPH's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993300Peter Greenleafwww.auriniapharma.com

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.

Aurinia Pharmaceuticals Inc. Fundamentals Summary

How do Aurinia Pharmaceuticals's earnings and revenue compare to its market cap?
AUPH fundamental statistics
Market capUS$1.07b
Earnings (TTM)-US$50.35m
Revenue (TTM)US$207.11m

5.1x

P/S Ratio

-20.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AUPH income statement (TTM)
RevenueUS$207.11m
Cost of RevenueUS$62.29m
Gross ProfitUS$144.82m
Other ExpensesUS$195.17m
Earnings-US$50.35m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)-0.35
Gross Margin69.92%
Net Profit Margin-24.31%
Debt/Equity Ratio0%

How did AUPH perform over the long term?

See historical performance and comparison